Cullen Capital Management, LLC, under the name Schafer Cullen Capital Management, Inc., released its third-quarter investor letter. The value equity strategy returned 6.9% gross and 6.8% net in the quarter, outperforming the Russell 1000 Value and S&P 500. Becton, Dickinson and Company (NYSE:BDX) was highlighted as a top stock pick, with a one-month return of 2.24%.

Becton, Dickinson and Company (NYSE:BDX) is a healthcare company specializing in medical supplies and diagnostic products. SCCM Value Equity Strategy noted Becton, Dickinson and Company (NYSE:BDX) as a key investment in its third-quarter 2025 investor letter. The stock closed at $192.33 per share on November 18, 2025, with a market cap of $55.127 billion.

SCCM Value Equity Strategy purchased Becton, Dickinson and Company (NYSE:BDX) due to its global presence in medical technology. The company’s segments focus on medication delivery, disease detection, and surgical devices. Becton, Dickinson and Company (NYSE:BDX) revenue grew by 7% to $5.9 billion in the fiscal fourth quarter of 2025. The stock is not among the 30 most popular stocks among hedge funds.

Hinde Group shared its investment thesis for Becton, Dickinson and Company (NYSE:BDX) in another article. For more investor letters from hedge funds and leading investors, visit the hedge fund investor letters Q3 2025 page. Check out The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money for more insights.

Read more at Yahoo Finance: What Makes Becton Dickinson (BDX) a Good Long-Term Investment?